Your browser doesn't support javascript.
loading
Interconnection between Cardiac Cachexia and Heart Failure-Protective Role of Cardiac Obesity.
Soto, María Elena; Pérez-Torres, Israel; Rubio-Ruiz, María Esther; Manzano-Pech, Linaloe; Guarner-Lans, Verónica.
Afiliação
  • Soto ME; Department of Immunology, Instituto Nacional de Cardiología "Ignacio Chávez", México City 14080, Mexico.
  • Pérez-Torres I; Department of Cardiovascular Biomedicine, Instituto Nacional de Cardiología "Ignacio Chávez", México City 14080, Mexico.
  • Rubio-Ruiz ME; Department of Physiology, Instituto Nacional de Cardiología "Ignacio Chávez", México City 14080, Mexico.
  • Manzano-Pech L; Department of Cardiovascular Biomedicine, Instituto Nacional de Cardiología "Ignacio Chávez", México City 14080, Mexico.
  • Guarner-Lans V; Department of Physiology, Instituto Nacional de Cardiología "Ignacio Chávez", México City 14080, Mexico.
Cells ; 11(6)2022 03 18.
Article em En | MEDLINE | ID: mdl-35326490
Cachexia may be caused by congestive heart failure, and it is then called cardiac cachexia, which leads to increased morbidity and mortality. Cardiac cachexia also worsens skeletal muscle degradation. Cardiac cachexia is the loss of edema-free muscle mass with or without affecting fat tissue. It is mainly caused by a loss of balance between protein synthesis and degradation, or it may result from intestinal malabsorption. The loss of balance in protein synthesis and degradation may be the consequence of altered endocrine mediators such as insulin, insulin-like growth factor 1, leptin, ghrelin, melanocortin, growth hormone and neuropeptide Y. In contrast to many other health problems, fat accumulation in the heart is protective in this condition. Fat in the heart can be divided into epicardial, myocardial and cardiac steatosis. In this review, we describe and discuss these topics, pointing out the interconnection between heart failure and cardiac cachexia and the protective role of cardiac obesity. We also set the basis for possible screening methods that may allow for a timely diagnosis of cardiac cachexia, since there is still no cure for this condition. Several therapeutic procedures are discussed including exercise, nutritional proposals, myostatin antibodies, ghrelin, anabolic steroids, anti-inflammatory substances, beta-adrenergic agonists, medroxyprogesterone acetate, megestrol acetate, cannabinoids, statins, thalidomide, proteasome inhibitors and pentoxifylline. However, to this date, there is no cure for cachexia.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Caquexia / Insuficiência Cardíaca Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cells Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Caquexia / Insuficiência Cardíaca Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Cells Ano de publicação: 2022 Tipo de documento: Article País de afiliação: México País de publicação: Suíça